News &amp; Updates

Combination treatment with sacubitril and valsartan appears to be no better than ramipril in reducing the risk of cardiovascular death and heart failure (HF) in patients with acute myocardial infarction (AMI) complicated by left ventricular dysfunction, regardless of AMI type, reveals a study.

Ramipril on par with sacubitril/valsartan in acute MI

05 Mar 2024

OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies

Omalizumab scores in the NIH*-sponsored phase III OUtMATCH** trial, increasing the threshold for an allergic reaction to peanut and other common food allergens in children and adults with multiple food allergies.

OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies

05 Mar 2024

Hysterectomy for low-risk cervical cancer: Less is more?

In patients with low-risk cervical cancer, simple hysterectomy has demonstrated noninferior pelvic recurrence rate at 3 years and lower rates of surgery-related urologic adverse events (AEs) vs radical hysterectomy in the phase III, randomized, noninferiority CX.5 SHAPE trial.

Hysterectomy for low-risk cervical cancer: Less is more?

05 Mar 2024

Low-fructose diet may be beneficial in obesity, hypertension

Sticking to a low-fructose diet helps improve several anthropometric and metabolic variables, which could have favourable effects on obesity and hypertension, according to a meta-analysis.

Low-fructose diet may be beneficial in obesity, hypertension

Nirmatrelvir reduces the risk of long COVID

Post-COVID condition, also known as long COVID, is a serious public health problem affecting millions of people around the world.¹

Nirmatrelvir reduces the risk of long COVID

Patient blood management is important in improving patient outcomes

The key to familiarizing patient blood management (PBM) among healthcare professionals may lie in identifying PBM as a crucial part of blood health, said Sherri Ozawa, clinical director of Patient Blood Management, Englewood Health, and founding member of the Society for the Advancement of Patient Blood Management (SABM).

Patient blood management is important in improving patient outcomes

05 Mar 2024

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

Adding lutetium-177 (¹⁷⁷Lu)–Dotatate radioligand therapy (RLT) to long-acting octreotide as first-line therapy significantly improves progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor-positive (SSTR+), grade 2 and 3 (G2 and G3), well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs) compared with high-dose long-acting octreotide alone, according to the NETTER-2 trial presented at ASCO GI 2024.

Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs

High-dose PPI use among cirrhotic patients poses risk of death, complications

Patients with cirrhosis who are exposed to high-dose proton pump inhibitors (PPIs) are at increased risk of death and cirrhotic complications, as suggested in a retrospective study.

High-dose PPI use among cirrhotic patients poses risk of death, complications

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

04 Mar 2024 by

Treatment with belzutifan helps patients with previously treated advanced renal cell carcinoma (RCC) achieve better disease-specific symptoms and quality of life (QoL) compared with everolimus, according to the patient-reported outcome (PRO) data from the phase III LITESPARK-005 trial.

Patient-reported outcomes in advanced RCC favour belzutifan over everolimus

Existing interventions insufficient in easing physician burnout

Several interventions for reducing physician burnout result in significant numerical improvements in some domains, but such improvements fall short of providing meaningful changes in clinical burnout, according to the results of a meta-analysis.

Existing interventions insufficient in easing physician burnout